Indivior PLC (NASDAQ:INDV) Receives $22.00 Average Target Price from Analysts

Shares of Indivior PLC (NASDAQ:INDV) have been assigned a consensus recommendation of “Buy” from the six analysts that are presently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $22.00.

A number of equities research analysts have weighed in on INDV shares. Craig Hallum lifted their target price on Indivior from $27.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 27th. Jefferies Financial Group started coverage on Indivior in a report on Tuesday, July 22nd. They issued a “buy” rating and a $20.00 target price for the company. Wall Street Zen upgraded Indivior from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 21st. Finally, HC Wainwright began coverage on Indivior in a report on Wednesday, August 6th. They issued a “buy” rating and a $27.00 target price for the company.

Indivior Stock Down 2.8%

Shares of NASDAQ:INDV opened at $23.21 on Wednesday. Indivior has a 12-month low of $7.33 and a 12-month high of $25.10. The business has a fifty day simple moving average of $20.79 and a 200 day simple moving average of $14.54.

Indivior (NASDAQ:INDV) last announced its earnings results on Thursday, July 31st. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.25. The business had revenue of $302.00 million during the quarter, compared to analyst estimates of $239.43 million. Indivior had a negative return on equity of 86.28% and a net margin of 6.65%. Indivior has set its FY 2025 guidance at EPS. On average, analysts forecast that Indivior will post 1.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Indivior

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Nomura Holdings Inc. bought a new position in shares of Indivior during the 2nd quarter worth about $7,602,000. Tower Research Capital LLC TRC raised its holdings in shares of Indivior by 851.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,567 shares of the company’s stock worth $156,000 after acquiring an additional 9,456 shares during the last quarter. Krensavage Asset Management LLC boosted its position in shares of Indivior by 0.9% during the second quarter. Krensavage Asset Management LLC now owns 974,474 shares of the company’s stock valued at $14,364,000 after buying an additional 9,106 shares during the last quarter. Rubric Capital Management LP grew its holdings in Indivior by 31.6% during the second quarter. Rubric Capital Management LP now owns 4,647,179 shares of the company’s stock worth $68,499,000 after buying an additional 1,117,140 shares in the last quarter. Finally, Gendell Jeffrey L grew its holdings in Indivior by 41.2% during the second quarter. Gendell Jeffrey L now owns 856,481 shares of the company’s stock worth $12,625,000 after buying an additional 250,000 shares in the last quarter. Institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.